Kinase inhibitors have given rise to an era of precision medicine for the treatment of cancer, but the ability of cancer cells to mutate enables tumors to develop resistance to existing therapies. Nuvalent is developing therapies that both target the original tumor as well tumors with emergent resistance. We spoke to James Porter, CEO of Nuvalent, about how it designs drugs that address the challenges of both kinase resistance and selectivity, its pipeline in development, and why it’s critical that its experimental therapy for non-small cell lung cancer can penetrate the brain.
How Solving a Problem with Genetic Medicines May Solve Another with Infectious Diseases
Boosting the Power of Dendritic Cancer Vaccines
Teaching an Old Drug a New Trick to Prevent Lyme Disease
A New Class of Cell Therapies to Target Solid Tumors
Targeting the Tumor Microenvironment with Lipid-Based Immunotherapies
A Company Born from a Father Who Wore His Heart on His Sleeve
Using AI to Improve Burn Care
A Home for Biotech in the City that Never Sleeps
Biopharma R&D Growing Stronger
The Benefits of Having a Multitude of Cins
Making ADCs Smarter and Safer with a Simple Twist of Fate
Targeting a Natural Repair System to Restore Brain Health
Programing Cells in a Predictable and Scalable Way
Why DNA May Be the Data Storage Medium of the Future
Scouring Genetic Variation within Our Cells for Drug Targets
Correcting Gene Dysregulation to Treat Diseases
Using Technology to Regain Abilities after Spinal Cord Injury
Why Drug Developers Have a Growing Interest in Targeting Mitochondria
Beefing Up Computational Muscle to Understand Molecular Activity of Drug Candidates
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Unexplainable
Stuff To Blow Your Mind
پادکست آذرخش مکری - azarakhsh mokri